Clinical trial NCT04532515: Seal-G / Seal-G MIST Study
Official title: Seal-G and Seal-G MIST Study for Reinforcement and Protection of Colonic Anastomoses in Subjects Undergoing Colonic Resection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colon Cancer
Gastrointestinal Cancer
Lead sponsor: Advanced Medical Solutions Ltd.
Sponsor class: INDUSTRY
Collaborators: name: ClinSearch
name: Advanced Medical Solutions Israel (Sealantis) Ltd.
First posted: 2020-08-31
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Seal-G Product Family variants will be used as the study device (Treatment) according to the following scheme:

1. Seal-G Surgical Sealant \[Seal-G\]- will be applied on colonic anastomosis created by extra-corporal approach.
2. Seal-G MIST System \[Seal-G MIST\]- will be applied on colonic anastomosis created by intra-corporal approach.

Intended Use: Seal-G/Seal-G MIST are surgical sealants intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.

Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis
Primary purpose: SUPPORTIVE_CARE

Brief summary: A prospective, multi-center, open label, study to evaluate safety and performance of Seal-G and Seal-G MIST in reinforcing colonic anastomosis, in subjects undergoing Colon Resection surgery

Detailed description: Seal-G and Seal-G MIST Surgical Sealants are intended for the reinforcement and protection of gastrointestinal anastomosis. The Seal-G and Seal-G MIST devices share the same Alginate based sealant technology and intended purpose. The devices only differ in their method of application, The Seal-G device is designed for spread application by extra-corporal approach, and the Seal-G MIST device is designed for spray application by intra-corporal approach.

The proposed Clinical Investigation aims to collect clinical evidence on the devices' usage, including safety, performance and usability.

Eligibility criteria: Inclusion Criteria:

1. Subject signs and dates a written ICF, indicates an understanding of the study procedures and follow-up requirements and is willing to comply with them.
2. Subject is aged 18 years to 80 years
3. Subject is scheduled for elective open or laparoscopic (including robotic) colon cancer resection surgery with primary anastomosis (excluding low anterior resection)

Exclusion Criteria:

1. Anastomosis is expected to be ≤ 10cm from anal verge
2. Surgery involves stoma creation
3. Subject who underwent a prior pelvic radiation therapy
4. Subject with a BMI \> 40 or \<19
5. Subject with ASA status higher than 3
6. Albumin level \< 3 gr/dl
7. Total bilirubin \>1.5 mg/dL
8. Hemoglobin level \< 8mg/dl on day of surgery
9. Subject has a diagnosis of bowel strangulation, peritonitis, bowel perforation, local or systemic infection, ischemic bowel, and carcinomatosis
10. Subject treated with immunosuppressive agents within 28 days prior to study enrollment (including corticosteroids)
11. Serious or uncontrolled co-existent diseases (e.g. severe cardiovascular disease, congestive heart failure, recent myocardial infarction within 6 months from surgery, significant vascular disease, active or uncontrolled autoimmune disease, active or uncontrolled infection, uncontrolled DM with episodes of hospitalization due to hypo or hyperglycemia within 6 months of surgery)
12. Subject known to have distant metastases, such as liver, lung, bone etc. metastases (not including local and regional lymph nodes)
13. Subject with known sensitivity to Indigo carmine dye (FD\&C 2/ E132)
14. Subject who according to the investigator clinical judgement is not suitable for participation in the study or is at risk
15. Subject requires more than one anastomosis during the surgery
16. Subject is scheduled for another surgery during the follow up period of this study
17. Subjects who cannot comply with study visits/ procedures or have poor compliance (e.g. mentally handicapped, prisoners, etc.)

Intraoperative Exclusion Criteria:

Subjects who meet any of the following intra-operative exclusion criteria will be considered as screen failures and will not be eligible for the study:

1. Positive leak test requires anastomosis takedown and/or re-anastomosis.
2. Additional resection (not including tissue biopsy) of non-colonic solid organ (e.g. Liver resection, uterus, bladder, seminal vesicle, ureter)
3. Subjects whom anastomosis is ≤10 cm from the anal verge
4. Subject received intraoperative sealant, glue or any buttressing material for the study related anastomosis, other than the Seal-G/Seal-G MIST
5. Subject received two or more units of PC transfusion during surgery
6. Subject has peritoneal carcinomatosis or any other metastasis observed by the surgeon

Primary outcomes:
measure: Proportion of surgeries with full sealant coverage - successful application
timeFrame: At time of surgery
Secondary outcomes:
measure: Proportion of subjects with clinical anastomotic leaks
timeFrame: Up to 30 days post-surgery
measure: Proportion of subjects with subclinical / radiological leaks
timeFrame: Up to 30 days post-surgery
measure: Proportion of subjects with at least one Serious Adverse Event
timeFrame: Up to 30 days post-surgery
measure: Proportion of subjects that had a reoperation
timeFrame: Up to 30 days post-surgery
measure: Hospital length of stay
timeFrame: Up to 30 days post-surgery
Other outcomes:
Locations:
city: Ramat Gan
country: Israel
facility: Sheba Medical Center (Tel Hashomer)
city: Rishon LeZion
country: Israel
facility: Shamir (Assaf Harofeh) Medical Center
Study officials:
affiliation: Advanced Medical Solutions Israel (Sealantis) Ltd.
name: Moshe Kamar, MD
role: STUDY_DIRECTOR
References: